|
KMID : 0624620190520050342
|
|
BMB Reports
2019 Volume.52 No. 5 p.342 ~ p.347
|
|
|
Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer
|
|
Kim Dong-Hyun
Kim Hye-Min
Huong Pham Thi Thu
Han Ho-Jin
Hwang Joon-Sung
Cha-Molstad Hyun-Joo
Lee Kyung-Ho
Ryoo In-Ja
Kim Kyoon-Eon
Huh Yang-Hoon
Ahn Jong-Seog
Kwon Yong-Tae
Soung Nak-Kyun
Kim Bo-Yeon
|
|
|
Abstract
|
|
|
|
Methylation is a primary epigenetic mechanism regulating gene expression. 5-aza-2'-deoxycytidine is an FDA-approved drug prescribed for treatment of cancer by inhibiting DNA-Methyl-Transferase 1 (DNMT1). Results of this study suggest that prolonged treatment with 5-aza-2'-deoxycytidine could induce centrosome abnormalities in cancer cells and that CEP131, a centrosome protein, is regulated by DNMT1. Interestingly, cancer cell growth was attenuated in vitro and in vivo by inhibiting the expression of Cep131. Finally, Cep131-deficient cells were more sensitive to treatment with DNMT1 inhibitors. These findings suggest that Cep131 is a potential novel anti-cancer target. Agents that can inhibit this protein may be useful alone or in combination with DNMT1 inhibitors to treat cancer.
|
|
|
KEYWORD
|
|
|
Anti-cancer, Centrosome, CEP131, DNMT1
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|